ストックスクリーナーアプリを入手
25.08
3.38%
-0.80
前日終値:
$25.88
開ける：
$26.84
24時間の取引高:
43.69M
Relative Volume:
1.56
時価総額：
$5.71B
収益：
$2.35B
当期純損益:
$128.37M
株価収益率:
48.04
EPS:
0.5221
ネットキャッシュフロー:
$57.42M
1週間 パフォーマンス:
+57.46%
1か月 パフォーマンス:
+58.26%
6か月 パフォーマンス:
-54.95%
1年 パフォーマンス:
-26.30%
1日の値動き範囲:
$24.63
$27.24
1週間の範囲:
$15.21
$27.54
52週間の値動き範囲:
$13.74
$70.43
Hims Hers Health Inc Stock (HIMS) Company Profile
Compare HIMS vs TAK, ZTS, HLN, TEVA, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
25.07 | 5.90B | 2.35B | 128.37M | 57.42M | 0.5221 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.80 | 57.24B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
116.80 | 50.57B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.10 | 44.54B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.43 | 35.49B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
544.88 | 23.87B | 3.13B | 1.27B | 1.12B | 26.39 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-09 | アップグレード | Needham | Hold → Buy |
| 2026-02-24 | ダウングレード | BTIG Research | Buy → Neutral |
| 2026-01-12 | 開始されました | Evercore ISI | In-line |
| 2025-12-09 | 開始されました | Barclays | Overweight |
| 2025-10-21 | 開始されました | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | ダウングレード | Needham | Buy → Hold |
| 2025-06-04 | 繰り返されました | Needham | Buy |
| 2025-04-29 | ダウングレード | TD Cowen | Buy → Hold |
| 2025-02-18 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | ダウングレード | Citigroup | Neutral → Sell |
| 2025-01-07 | 開始されました | BTIG Research | Buy |
| 2024-12-17 | 開始されました | Morgan Stanley | Overweight |
| 2024-11-14 | ダウングレード | BofA Securities | Buy → Underperform |
| 2024-08-22 | 開始されました | Needham | Buy |
| 2024-08-09 | ダウングレード | Imperial Capital | Outperform → In-line |
| 2024-05-22 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-04-16 | ダウングレード | Jefferies | Buy → Hold |
| 2024-04-10 | 開始されました | Canaccord Genuity | Buy |
| 2024-02-28 | アップグレード | Imperial Capital | In-line → Outperform |
| 2024-02-26 | 開始されました | Leerink Partners | Market Perform |
| 2023-12-07 | 開始されました | Imperial Capital | In-line |
| 2023-07-28 | 開始されました | TD Cowen | Outperform |
| 2023-04-11 | 開始されました | Robert W. Baird | Neutral |
| 2023-02-09 | アップグレード | Jefferies | Hold → Buy |
| 2022-11-08 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-11-08 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | 開始されました | Truist | Hold |
| 2022-07-15 | 開始されました | SVB Leerink | Underperform |
| 2022-04-14 | 開始されました | Guggenheim | Buy |
| 2022-04-01 | 再開されました | Credit Suisse | Outperform |
| 2022-03-10 | 開始されました | Deutsche Bank | Hold |
| 2021-12-02 | 開始されました | Jefferies | Hold |
| 2021-11-11 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | 開始されました | BofA Securities | Neutral |
| 2021-05-20 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | 開始されました | Truist | Hold |
| 2021-03-09 | 開始されました | Credit Suisse | Neutral |
| 2021-03-02 | アップグレード | Citigroup | Neutral → Buy |
| 2021-02-17 | 開始されました | Citigroup | Neutral |
| 2021-02-12 | 開始されました | Piper Sandler | Neutral |
| 2021-02-08 | 開始されました | Tigress Financial | Buy |
すべてを表示
Hims Hers Health Inc (HIMS) 最新ニュース
Why Hims & Hers Health (HIMS) Stock Is Surging In Thursday's Premarket - Benzinga
Obesity Drugs Are Getting Easier and Cheaper to Find - Bloomberg.com
Hims & Hers Health (HIMS) Stock Up 7% Premarket Thursday, On Track for Best Week Ever - CoinCentral
Trending tickers: Nebius Group, Hims & Hers, BMW, Savills and On The Beach - Yahoo Finance UK
Hims & Hers (HIMS) soars 10.3% on analyst upgrades, new deal - MSN
Hims & Hers revamps GLP-1 strategy with Novo Nordisk - TipRanks
JPMorgan Chase & Co. Significantly Reduces Stake in Hims & Hers Health Inc. - GuruFocus
Hims & Hers (HIMS) Soars 10.3% on Analyst Upgrades, New Deal - Insider Monkey
A Look At Novo Nordisk’s Valuation After Hims & Hers GLP 1 Distribution Agreement - simplywall.st
Lucid Tops The Most-Shorted Stock List—Here Are 9 More Short Targets - Benzinga
Hims & Hers Hires Ex-Eli Lilly Communications Chief Amid Obesity Drug Strategy Shift - GuruFocus
Hims & Hers Stock Skyrockets as Landmark Settlement with Novo Nordisk Ends Weight-Loss Drug War - FinancialContent
Hims & Hers C-suite shake-up, Stryker outage may be Iran-backed - Yahoo Finance
HIMS Stock Jumps 14% – Barclays Says Market Is Underestimating Opportunity From New Products - Stocktwits
3 Big Reasons to Love Hims & Hers Health (HIMS) - Yahoo Finance
HIMS Jumps 14.5% Following Strong Market Interest - GuruFocus
Hims & Hers: The Novo Nordisk Deal Changes Everything (NYSE:HIMS) - Seeking Alpha
Hims & Hers Brings In Lilly Communications Veteran - GuruFocus
Hims & Hers Health (NYSE:HIMS) Stock Price Expected to Rise, Barclays Analyst Says - MarketBeat
Barclays Raises Price Target for HIMS: Maintains Overweight Rati - GuruFocus
Hims & Hers Health Stock Is Surging Wednesday: What's Going On? - Benzinga
Hims & Hers Health (NYSE:HIMS) Shares Up 11.5% After Analyst Upgrade - MarketBeat
This Novo Nordisk Partnership Shows That HIMS Has All The Leverage (NYSE:HIMS) - Seeking Alpha
Barclays Raises Hims & Hers (HIMS) Target to $29 After Novo Deal Clears Legal Overhang — Canaccord Cuts Progyny (PGNY) on Cautious 2026 Outlook - AOL.com
Can Novo Nordisk's Hims & Hers Deal Revive Its GLP-1 Momentum? - Yahoo! Finance Canada
Short Seller Who Bet Against Hims & Hers Now Says Its CEO 'Wiped The Floor' With Novo Nordisk - Stocktwits
Hims And Hers Taps Veteran Communicator To Shape GLP 1 Growth Story - simplywall.st
Hims & Hers Health, Inc. (NYSE:HIMS) Given Consensus Rating of "Hold" by Analysts - MarketBeat
HIMS Stock Just Exploded — But the Real Story Might Be the Novo Nordisk Deal - TS Avisen
Hims & Hers appoints Kathryn Beiser as communications chief - Investing.com
Hims & Hers Names Kathryn Beiser as Chief Communications Officer - Business Wire
Hims Hires Ex-Lilly PR Chief as Its Weight-Loss Strategy Shifts - Bloomberg.com
Hims & Hers Expands Health Platform with Major Novo Nordisk Deal - StocksToTrade
Hims & Hers Health: The GLP-1 Chaos Is Fading, The Thesis Is Still On Track (NYSE:HIMS) - Seeking Alpha
Asset Manager Exits Shares of Hims & Hers Health - Yahoo Finance
What's Driving Attention Behind These Trending Stocks? MRVL, STRL, HIMS - Finviz
Hims & Hers Health Soars with Novo Nordisk Partnership Plans - timothysykes.com
Hims & Hers Stock Upgraded After Novo Nordisk Agreement. Why It Isn’t a Buy Yet. - Barron's
Patience Pays: Hims & Hers Surges on News of Novo Nordisk Deal - MarketBeat
Hims and Hers Expands Consumer-Focused Digital Health Platform - Yahoo Finance
What's Fueling The Rise In Hims & Hers Health Stock Today? - Benzinga
Hims & Hers upgraded to Buy from Hold at Needham - Yahoo Finance
Hims & Hers Health (NYSE:HIMS) Sees Strong Trading Volume on Analyst Upgrade - MarketBeat
Disrupting the Pharmacy: A Deep-Dive into Hims & Hers Health (HIMS) in 2026 - FinancialContent
Hims & Hers Health (NYSE:HIMS) Upgraded at Citigroup - MarketBeat
Novo Nordisk and Hims & Hers Partner to Expand Semaglutide Access - Pharmaceutical Commerce
Introducing Hims & Hers Benefits, Unlocking Health & Wellness Discounts for Subscribers - HIMS Investor Relations
With Hims & Hers Benefits, holistic health starts here - Hims & Hers Newsroom
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Deutsche Bank Aktiengesellschaft Issues Positive Forecast for Hims & Hers Health (NYSE:HIMS) Stock Price - MarketBeat
Hims & Hers Health (NYSE:HIMS) Raised to "Neutral" at Bank of America - MarketBeat
Hims Hers Health Inc (HIMS) 財務データ
収益
当期純利益
現金流量
EPS
3.04%
2.13%
大文字化:
|
ボリューム (24 時間):